CO5601001A2 - Agentes de produccion de imagenes dirigidas a integrinas - Google Patents

Agentes de produccion de imagenes dirigidas a integrinas

Info

Publication number
CO5601001A2
CO5601001A2 CO04080978A CO04080978A CO5601001A2 CO 5601001 A2 CO5601001 A2 CO 5601001A2 CO 04080978 A CO04080978 A CO 04080978A CO 04080978 A CO04080978 A CO 04080978A CO 5601001 A2 CO5601001 A2 CO 5601001A2
Authority
CO
Colombia
Prior art keywords
ligand
integrins
nanoparticles
pat
images directed
Prior art date
Application number
CO04080978A
Other languages
English (en)
Inventor
Gregory Lanza
Samuel A Wickline
Tom Harris
Original Assignee
Barnes Jewish Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Barnes Jewish Hospital filed Critical Barnes Jewish Hospital
Publication of CO5601001A2 publication Critical patent/CO5601001A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Acoustics & Sound (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

1.- Un método para suministrar una emulsión que comprende nanopartículas a un tejido objetivo, en donde dicho tejido objetivo se caracteriza por altos niveles de integrina avß3, cuyo método comprende administrar a un sujeto que comprende tal tejido una emulsión de nanopartículas en donde dichas nanopartículas están acopladas a un ligando específico para una integrina avß3, con la condición de que dicho ligando es diferente a un anticuerpo o fragmento de éste.2.- El método de la reivindicación 1, en donde dicho ligando es un ligando no péptido.3.- El método de la reivindicación 2, en donde el ligando es un compuesto de fórmula (1) como se estableció en la U.S. 6,130,231, o un compuesto como se estableció en la reivindicación 1 de la patente U. S. 6,153,628 o la patente U.S. 6,322,770; todas incorporadas aquí como referencia.
CO04080978A 2002-01-24 2004-08-19 Agentes de produccion de imagenes dirigidas a integrinas CO5601001A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35139002P 2002-01-24 2002-01-24

Publications (1)

Publication Number Publication Date
CO5601001A2 true CO5601001A2 (es) 2006-01-31

Family

ID=27613494

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04080978A CO5601001A2 (es) 2002-01-24 2004-08-19 Agentes de produccion de imagenes dirigidas a integrinas

Country Status (14)

Country Link
US (3) US7255875B2 (es)
EP (2) EP2269659A1 (es)
JP (2) JP4731117B2 (es)
KR (1) KR100978126B1 (es)
CN (2) CN100356984C (es)
AU (2) AU2003209392B2 (es)
BR (1) BR0307206A (es)
CA (1) CA2474386C (es)
CO (1) CO5601001A2 (es)
MX (1) MXPA04007188A (es)
NZ (1) NZ534500A (es)
TR (1) TR200401834T2 (es)
WO (1) WO2003062198A1 (es)
ZA (1) ZA200406686B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US7220401B2 (en) * 1999-09-24 2007-05-22 Barnes-Jewish Hospital Blood clot-targeted nanoparticles
US20080247943A1 (en) * 1999-09-24 2008-10-09 Gregory Lanza Blood Clot-Targeted Nanoparticles
US7951061B2 (en) * 2001-07-25 2011-05-31 Allan Foreman Devices for targeted delivery of thermotherapy, and methods related thereto
US7731648B2 (en) * 2001-07-25 2010-06-08 Aduro Biotech Magnetic nanoscale particle compositions, and therapeutic methods related thereto
CN100356984C (zh) * 2002-01-24 2007-12-26 巴内斯－朱威胥医院 整联蛋白靶向的影像剂
US6869591B2 (en) * 2002-03-26 2005-03-22 Barnes-Jewish Hospital Paramagnetic particles that provide improved relaxivity
AU2004263136A1 (en) * 2003-08-08 2005-02-17 Barnes-Jewish Hospital Emulsion particles for imaging and therapy and methods of use thereof
CA2559889A1 (en) * 2004-01-16 2005-08-25 Barnes-Jewish Hospital Targeted atherosclerosis treatment
CN101031287A (zh) * 2004-03-02 2007-09-05 麻省理工学院 纳米细胞药物递送系统
US20070053845A1 (en) * 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
AU2005253962A1 (en) * 2004-06-09 2005-12-29 Kereos, Inc. Lipophilic derivatives of chelate monoamides
US20060047025A1 (en) * 2004-06-29 2006-03-02 Matthew Piazza Viscous materials and method for producing
WO2006096499A2 (en) * 2005-03-04 2006-09-14 Washington University Mr coronary angiography with a fluorinated nanoparticle contrast agent at 1.5 t
WO2006099445A2 (en) * 2005-03-14 2006-09-21 Massachusetts Institute Of Technology Nanocells for diagnosis and treatment of diseases and disorders
FR2883562B1 (fr) 2005-03-24 2009-02-27 Guerbet Sa Chelates lipophiles et leur utilisation en imagerie
CA2602385A1 (en) * 2005-03-29 2006-10-05 The Research Foundation Of State University Of New York Hybrid inorganic nanoparticles, methods of using and methods of making
ATE455307T1 (de) * 2005-04-26 2010-01-15 Koninkl Philips Electronics Nv Verfahren zur verwendung von cest-kontrastmitteln bei der magnetresonanztomographie
US8306603B2 (en) * 2005-04-26 2012-11-06 Koninklijke Philips Electronics N.V. MRI involving contrast agent with time modulated contrast enhancement
JP2007079857A (ja) * 2005-09-13 2007-03-29 Canon Inc サーバー装置、クライアント装置及びそれらの制御方法、コンピュータプログラム、記憶媒体
EP2308513A3 (de) * 2005-11-16 2011-11-23 Signalomics GmbH Fluoreszenz-Nanopartikel
ES2627998T3 (es) 2005-11-16 2017-08-01 Exchange Imaging Technologies Gmbh Nanopartículas fluorescentes
AU2006320488A1 (en) * 2005-12-02 2007-06-07 Barnes-Jewish Hospital Methods to ameliorate and image angioplasty-induced vascular injury
WO2007079437A2 (en) * 2006-01-03 2007-07-12 Kereos, Inc. Combination antitumor therapies
US20070232909A1 (en) * 2006-03-28 2007-10-04 Washington University Ultrasonic Characterization of Internal Body Conditions Using Information Theoretic Signal Receivers
US8003078B2 (en) 2006-03-29 2011-08-23 Barnes-Jewish Hospital Targeted MR imaging agents
CA2650574A1 (en) * 2006-04-27 2007-11-08 Barnes-Jewish Hospital Detection and imaging of target tissue
CA2667209A1 (en) * 2006-10-24 2008-06-12 Kereos, Inc. Improved linkers for anchoring targeting ligands
EP2080767A4 (en) * 2006-11-09 2012-03-28 Daiichi Sankyo Co Ltd COMPOSITION FOR THE INTRODUCTION OF NUCLEIC ACID
AU2008206064A1 (en) * 2007-01-19 2008-07-24 Triton Biosystems, Inc. Thermotherapy susceptors and methods of using same
US20080305046A1 (en) * 2007-02-16 2008-12-11 Ali Hafezi-Moghadam Molecular imaging methods for diagnosis and evaluation of ocular and systemic diseases
US8372427B2 (en) 2007-03-05 2013-02-12 Abbott Cardiovascular Systems Inc. Therapeutic composition with enhanced endothelium targeting
AU2008222822A1 (en) 2007-03-05 2008-09-12 Washington University Nanoparticle delivery systems for membrane-integrating peptides
FR2914304B1 (fr) 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
FR2914303A1 (fr) 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
WO2009151788A2 (en) * 2008-04-22 2009-12-17 The Washington University Universal anchor peptide for nanoparticles
US9125949B2 (en) * 2008-12-30 2015-09-08 University Of North Texas Direct utilization of plasma proteins for the in vivo assembly of protein-drug/imaging agent conjugates, nanocarriers and coatings for biomaterials
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
EP2485768A1 (en) * 2009-10-07 2012-08-15 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding lipid compounds
WO2011071778A1 (en) 2009-12-07 2011-06-16 Mayo Foundation For Medical Education And Research Device for the delineation of cardiovascular or other anatomical structures
FR2968562B1 (fr) 2010-12-14 2013-01-11 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de muc5ac
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
SG10202010626PA (en) * 2011-03-31 2020-11-27 Schaefer Konstanze Perfluorinated compounds for the non-viral transfer of nucleic acids
WO2012177837A2 (en) 2011-06-21 2012-12-27 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
FR2980365B1 (fr) 2011-09-26 2016-02-12 Guerbet Sa Nanoemulsions, leur procede de preparation, et leur utilisation comme agent de contraste.
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR3000688B1 (fr) * 2013-01-08 2016-09-30 Centre Nat De La Rech Scient - Cnrs - Procede pour activer une reaction chimique, melange activable par ce procede et dispostiif pour la mise en oeuvre de ce procede
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
WO2014186435A2 (en) 2013-05-14 2014-11-20 University Of Georgia Research Foundation, Inc. Compositions and methods for reducing neointima formation
CA2947494C (en) 2014-05-02 2020-10-20 Research Institute At Nationwide Children's Hospital Compositions and methods for anti-lyst immunomodulation
US10449269B2 (en) 2016-08-29 2019-10-22 Yale University Particle conjugated prosthetic patches and methods of making and using thereof
NZ759001A (en) * 2017-04-28 2023-03-31 Texas Children’s Hospital Targeting nanoparticles
WO2019232362A1 (en) * 2018-05-31 2019-12-05 University Of South Florida Nanoparticle delivery system for diseases associated with major basement membrane components of blood vessels accessible from blood stream
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
CN110433296A (zh) * 2019-08-16 2019-11-12 哈尔滨医科大学 一种19f-mr/荧光多模式分子成像及载药的诊疗一体化纳米探针及制备方法和应用
EP4351654A1 (en) * 2021-06-09 2024-04-17 Crinetics Pharmaceuticals, Inc. Non-peptide targeted therapeutics and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US613023A (en) 1898-10-25 Wire clothes-pin
AU6621586A (en) 1985-11-18 1987-06-02 University Of Texas System, The Polychelating agents for image and spectral enhancement (and spectral shift)
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
US4927623A (en) 1986-01-14 1990-05-22 Alliance Pharmaceutical Corp. Dissolution of gas in a fluorocarbon liquid
US5171755A (en) 1988-04-29 1992-12-15 Hemagen/Pfc Emulsions of highly fluorinated organic compounds
US5114703A (en) 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
US5087440A (en) 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5409688A (en) 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
US5304325A (en) 1991-11-13 1994-04-19 Hemagen/Pfc Emulsions containing alkyl- or alkylglycerophosphoryl choline surfactants and methods of use
US5403575A (en) 1991-12-12 1995-04-04 Hemagen/Pfc Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of using them
JPH08504811A (ja) * 1992-12-24 1996-05-28 ヘマジェン／ピーエフシー フルオロカーボンのエマルジョン
IL106578A (en) 1993-08-03 2000-08-13 Yissum Res Dev Co Pharmaceutical compositions for drug targeting
EP0702677A1 (en) 1994-04-08 1996-03-27 BRACCO International B.V. Aromatic amide compounds and metal chelates thereof
US5571498A (en) 1994-06-02 1996-11-05 Hemagen/Pfc Emulsions of paramagnetic contrast agents for magnetic resonance imaging (MRI).
US5614170A (en) 1994-11-30 1997-03-25 Hemagen/Pfc Paramagnetic complexes of N-alkyl-N-hydroxylamides of organic acids and emulsions containing same for magnetic resonance imaging (MRI)
US5520904A (en) * 1995-01-27 1996-05-28 Mallinckrodt Medical, Inc. Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
JP4215820B2 (ja) * 1995-06-07 2009-01-28 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 診断的および治療的使用のための新規な標的化組成物
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US5958371A (en) 1995-06-08 1999-09-28 Barnes-Jewish Hospital Site specific binding system, nuclear imaging compositions and methods
US5780010A (en) 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
US6821506B2 (en) * 1995-06-08 2004-11-23 Barnes-Jewish Hospital Site specific binding system, imaging compositions and methods
US5690907A (en) 1995-06-08 1997-11-25 The Jewish Hospital Of St. Louis Avidin-biotin conjugated emulsions as a site specific binding system
WO1998023608A1 (en) * 1996-11-27 1998-06-04 Dupont Pharmaceuticals Company Novel integrin receptor antagonists
JP2001521520A (ja) 1997-04-11 2001-11-06 ジー．ディー．サール アンド カンパニー 抗α▲下ｖ▼β▲下３▼インテグリン抗体アンタゴニスト
JP2001524481A (ja) 1997-11-26 2001-12-04 デュポン ファーマシューティカルズ カンパニー αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類
IL138093A0 (en) 1998-03-31 2001-10-31 Du Pont Pharm Co Pharmaceuticals for the imaging of angiogenic disorders
US6056939A (en) 1998-08-28 2000-05-02 Desreux; Jean F. Self-assembling heteropolymetallic chelates as imaging agents and radiopharmaceuticals
EP1140864A2 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
DE69936148T2 (de) 1998-12-18 2008-01-24 Bristol-Myers Squibb Pharma Co. Vitronektinrezeptorantagonist-arzneimittel
CA2727746A1 (en) * 1998-12-18 2000-06-22 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
ATE290879T1 (de) * 1999-08-18 2005-04-15 Altarex Medical Corp Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
WO2001097848A2 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
AU2002241576A1 (en) 2000-11-20 2002-06-11 Board Of Regents University Of Texas System Paramagnetic metal ion-based macrocyclic contrast agents
US7179449B2 (en) 2001-01-30 2007-02-20 Barnes-Jewish Hospital Enhanced ultrasound detection with temperature-dependent contrast agents
HUP0401904A3 (en) * 2001-08-08 2009-01-28 Bristol Myers Squibb Pharma Co Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
CN100356984C (zh) * 2002-01-24 2007-12-26 巴内斯－朱威胥医院 整联蛋白靶向的影像剂

Also Published As

Publication number Publication date
CA2474386C (en) 2011-07-05
US7255875B2 (en) 2007-08-14
US20080175792A1 (en) 2008-07-24
US20040058951A1 (en) 2004-03-25
US7566442B2 (en) 2009-07-28
KR100978126B1 (ko) 2010-08-26
JP2010248248A (ja) 2010-11-04
WO2003062198A1 (en) 2003-07-31
CN100356984C (zh) 2007-12-26
US7344698B2 (en) 2008-03-18
EP1572639A4 (en) 2006-08-09
BR0307206A (pt) 2004-12-21
JP5444154B2 (ja) 2014-03-19
TR200401834T2 (tr) 2005-10-21
WO2003062198A8 (en) 2003-11-06
MXPA04007188A (es) 2005-10-18
CA2474386A1 (en) 2003-07-31
AU2003209392B2 (en) 2008-10-09
WO2003062198A3 (en) 2005-08-04
EP2269659A1 (en) 2011-01-05
KR20040090986A (ko) 2004-10-27
EP1572639A1 (en) 2005-09-14
JP2005525319A (ja) 2005-08-25
ZA200406686B (en) 2005-09-19
JP4731117B2 (ja) 2011-07-20
US20060147380A1 (en) 2006-07-06
CN101249269A (zh) 2008-08-27
NZ534500A (en) 2007-07-27
CN1738815A (zh) 2006-02-22
AU2009200095A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
CO5601001A2 (es) Agentes de produccion de imagenes dirigidas a integrinas
Ke et al. Mitigation of amyloidosis with nanomaterials
ES2536206T3 (es) Parche medicinal
ES2572980T3 (es) Combinación de inhibidores de la proteasa del VHC con un tensioactivo
BR0310088A (pt) Pré-direcionamento de droga por meio de anticorpos biespecìficos e constructos haptênicos compreendendo um veìculo peptìdico e o(s) agente(s) ativo(s)
CY1118007T1 (el) Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων
SMT201300096B (it) Inibitori di prolil idrossilasi
ES2552651T3 (es) Composición inyectable de polidesoxirribonucleótido para el tratamiento de enfermedades osteoarticulares
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
GT200800058A (es) Diarilurea para el tratamiento de hipertensión pulmonar
BRPI0517091B8 (pt) composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida
AR054141A1 (es) Terapia combinada para el tratamiento de trastornos inmunoinflamatorios
PE20141159A1 (es) Metodos para tratar o prevenir trastornos relacionados con el colesterol
MY166045A (en) Abeta antibody formulation
AR056806A1 (es) Moleculas quimericas de anticuerpo rankl- pth/ pthrp
CY1112911T1 (el) Θεραπευτικος παραγοντας ηπατικης νοσου, που περιεχει παραγωγο 2-αμινο-1,3-προπανοδιολης ως δραστικο συστατικο
PE20091964A1 (es) Encapsulacion de agentes biologicamente activos
ES2544954T3 (es) Péptidos multiméricos ramificados para diagnóstico y terapia de tumores
AR074778A1 (es) Composicion farmaceutica, con anticuerpo monoclonal humano anti - igf-ir.
ES2531516T3 (es) Uso de escina
CY1108156T1 (el) Στερεοεκλεκτικη συνθεση αναλογων βιταμινης d
ATE538811T1 (de) Zytotoxizitätsvermittlung von zellen mit hinweisen auf oberflächenexpression von cd44
ECSP066476A (es) Preparación de una infusión que comprende ácido (2r)-2-propiloctanoico como ingrediente activo

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed